122 related articles for article (PubMed ID: 26238980)
1. Discovery of a series of novel compounds with moderate anti-hepatitis C virus NS3 protease activity in vitro.
Shi F; Zhang Y; Xu W
Bioorg Med Chem; 2015 Sep; 23(17):5539-45. PubMed ID: 26238980
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and antiviral evaluation of a novel series of homoserine-based inhibitors of the hepatitis C virus NS3/4A serine protease.
Alexandre FR; Brandt G; Caillet C; Chaves D; Convard T; Derock M; Gloux D; Griffon Y; Lallos L; Leroy F; Liuzzi M; Loi AG; Moulat L; Musiu C; Parsy C; Rahali H; Roques V; Seifer M; Standring D; Surleraux D
Bioorg Med Chem Lett; 2015 Sep; 25(18):3984-91. PubMed ID: 26231161
[TBL] [Abstract][Full Text] [Related]
3. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
Dahl G; Sandström A; Akerblom E; Danielson UH
Antivir Ther; 2007; 12(5):733-40. PubMed ID: 17713156
[TBL] [Abstract][Full Text] [Related]
4. Potent inhibitors of the hepatitis C virus NS3 protease: use of a novel P2 cyclopentane-derived template.
Johansson PO; Bäck M; Kvarnström I; Jansson K; Vrang L; Hamelink E; Hallberg A; Rosenquist A; Samuelsson B
Bioorg Med Chem; 2006 Aug; 14(15):5136-51. PubMed ID: 16675222
[TBL] [Abstract][Full Text] [Related]
5. Phosphorous acid analogs of novel P2-P4 macrocycles as inhibitors of HCV-NS3 protease.
Pompei M; Francesco ME; Koch U; Liverton NJ; Summa V
Bioorg Med Chem Lett; 2009 May; 19(9):2574-8. PubMed ID: 19328685
[TBL] [Abstract][Full Text] [Related]
6. Discovery of achiral inhibitors of the hepatitis C virus NS3 protease based on 2(1H)-pyrazinones.
Ortqvist P; Gising J; Ehrenberg AE; Vema A; Borg A; Karlén A; Larhed M; Danielson UH; Sandström A
Bioorg Med Chem; 2010 Sep; 18(17):6512-25. PubMed ID: 20673728
[TBL] [Abstract][Full Text] [Related]
7. Discovery of GS-9451: an acid inhibitor of the hepatitis C virus NS3/4A protease.
Sheng XC; Appleby T; Butler T; Cai R; Chen X; Cho A; Clarke MO; Cottell J; Delaney WE; Doerffler E; Link J; Ji M; Pakdaman R; Pyun HJ; Wu Q; Xu J; Kim CU
Bioorg Med Chem Lett; 2012 Apr; 22(7):2629-34. PubMed ID: 22366653
[TBL] [Abstract][Full Text] [Related]
8. Analogs design, synthesis and biological evaluation of peptidomimetics with potential anti-HCV activity.
Lasheen DS; Ismail MA; Abou El Ella DA; Ismail NS; Eid S; Vleck S; Glenn JS; Watts AG; Abouzid KA
Bioorg Med Chem; 2013 May; 21(10):2742-55. PubMed ID: 23583031
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors.
Avolio S; Robertson K; Hernando JI; DiMuzio J; Summa V
Bioorg Med Chem Lett; 2009 Apr; 19(8):2295-8. PubMed ID: 19285390
[TBL] [Abstract][Full Text] [Related]
10. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus.
Tsantrizos YS
Acc Chem Res; 2008 Oct; 41(10):1252-63. PubMed ID: 18681464
[TBL] [Abstract][Full Text] [Related]
11. Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents.
Lampa A; Ehrenberg AE; Gustafsson SS; Vema A; Kerblom E; Lindeberg G; Karlén A; Danielson UH; Sandström A
Bioorg Med Chem; 2010 Jul; 18(14):5413-24. PubMed ID: 20541424
[TBL] [Abstract][Full Text] [Related]
12. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles.
Chen KX; Njoroge FG; Arasappan A; Venkatraman S; Vibulbhan B; Yang W; Parekh TN; Pichardo J; Prongay A; Cheng KC; Butkiewicz N; Yao N; Madison V; Girijavallabhan V
J Med Chem; 2006 Feb; 49(3):995-1005. PubMed ID: 16451065
[TBL] [Abstract][Full Text] [Related]
13. In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease.
Liu R; Abid K; Pichardo J; Pazienza V; Ingravallo P; Kong R; Agrawal S; Bogen S; Saksena A; Cheng KC; Prongay A; Njoroge FG; Baroudy BM; Negro F
J Antimicrob Chemother; 2007 Jan; 59(1):51-8. PubMed ID: 17151003
[TBL] [Abstract][Full Text] [Related]
14. Establishment and application of high throughput screening model for hepatitis C virus NS3-4A protease inhibitors in vitro.
Jian-rui L; Yan-bin W; Shu-yi S; Hong-shan C; Jian-dong J; Zong-gen B
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Feb; 33(1):98-101. PubMed ID: 21375947
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease.
Li X; Zhang YK; Liu Y; Zhang S; Ding CZ; Zhou Y; Plattner JJ; Baker SJ; Liu L; Bu W; Kazmierski WM; Wright LL; Smith GK; Jarvest RL; Duan M; Ji JJ; Cooper JP; Tallant MD; Crosby RM; Creech K; Ni ZJ; Zou W; Wright J
Bioorg Med Chem Lett; 2010 Dec; 20(24):7493-7. PubMed ID: 21041080
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides: A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus.
Wang AX; Chen J; Zhao Q; Sun LQ; Friborg J; Yu F; Hernandez D; Good AC; Klei HE; Rajamani R; Mosure K; Knipe JO; Li D; Zhu J; Levesque PC; McPhee F; Meanwell NA; Scola PM
Bioorg Med Chem Lett; 2017 Feb; 27(3):590-596. PubMed ID: 28011221
[TBL] [Abstract][Full Text] [Related]
17. Generation of a novel poliovirus with a requirement of hepatitis C virus protease NS3 activity.
Hahm B; Back SH; Lee TG; Wimmer E; Jang SK
Virology; 1996 Dec; 226(2):318-26. PubMed ID: 8955051
[TBL] [Abstract][Full Text] [Related]
18. Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle.
McGivern DR; Masaki T; Lovell W; Hamlett C; Saalau-Bethell S; Graham B
J Virol; 2015 May; 89(10):5362-70. PubMed ID: 25740995
[TBL] [Abstract][Full Text] [Related]
19. Novel potent inhibitors of hepatitis C virus (HCV) NS3 protease with cyclic sulfonyl P3 cappings.
Chen KX; Vibulbhan B; Yang W; Nair LG; Tong X; Cheng KC; Njoroge FG
Bioorg Med Chem Lett; 2009 Feb; 19(4):1105-9. PubMed ID: 19168351
[TBL] [Abstract][Full Text] [Related]
20. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
López-Labrador FX; Moya A; Gonzàlez-Candelas F
Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]